Clinical TrialsThe Phase IIa CANAL study of Haduvio in IPF chronic cough already demonstrated its potential as best-in-indication, reaching an encouraging, statistically significant treatment effect in cough frequency reduction.
Financial PerformanceTRVI ended 1Q24 with $72.8M of cash, cash equivalents, and marketable securities and reaffirmed sufficient cash runway into 2026.
Market OpportunitiesHaduvio’s potential in additional indications, including RCC, could drive long-term value for TRVI shares.